1168PPhase I/II study of CTLA-4 inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in patients with advanced/refractory solid tumors, with expansion into 2L cervical cancer and solid tumors.

Saved in:
Bibliographic Details
Title: 1168PPhase I/II study of CTLA-4 inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in patients with advanced/refractory solid tumors, with expansion into 2L cervical cancer and solid tumors.
Authors: Coward, J1 (AUTHOR), Lemech, C2 (AUTHOR), Meniawy, T3 (AUTHOR), Dupont, C D4 (AUTHOR), Gonzalez, A M5 (AUTHOR), Lim, M6 (AUTHOR), Savitsky, D4 (AUTHOR), Carini, M7 (AUTHOR), Hu, S8 (AUTHOR), Shebanova, O9 (AUTHOR)
Source: Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1093/annonc/mdy288.041